Ikapharmindo Putramas Tbk.
PT Ikapharmindo Putramas Tbk engages in the research and development, manufacturing, and marketing of pharmaceutical products in Indonesia. It operates through three segments: Non Pharma, Pharma, and Contract Manufacturing. The company offers prescription medicines in the areas of neurology, psychiatry, dermatology, nephrology, gastroenterology, cardiology, pulmonology, antibiotics, generics, and… Read more
Ikapharmindo Putramas Tbk. (IKPM) - Net Assets
Latest net assets as of June 2025: Rp236.96 Billion IDR
Based on the latest financial reports, Ikapharmindo Putramas Tbk. (IKPM) has net assets worth Rp236.96 Billion IDR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp476.89 Billion) and total liabilities (Rp239.93 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp236.96 Billion |
| % of Total Assets | 49.69% |
| Annual Growth Rate | 18.01% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 18.96 |
Ikapharmindo Putramas Tbk. - Net Assets Trend (2022–2024)
This chart illustrates how Ikapharmindo Putramas Tbk.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ikapharmindo Putramas Tbk. (2022–2024)
The table below shows the annual net assets of Ikapharmindo Putramas Tbk. from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp246.12 Billion | +0.58% |
| 2023-12-31 | Rp244.71 Billion | +38.49% |
| 2022-12-31 | Rp176.70 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ikapharmindo Putramas Tbk.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp45.59 Billion | 18.52% |
| Common Stock | Rp168.47 Billion | 68.45% |
| Other Components | Rp32.07 Billion | 13.03% |
| Total Equity | Rp246.12 Billion | 100.00% |
Ikapharmindo Putramas Tbk. Competitors by Market Cap
The table below lists competitors of Ikapharmindo Putramas Tbk. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Toppoint Holdings Inc.
NYSE MKT:TOPP
|
$4.43 Million |
|
MILIBOO. S.A. EO -10
F:7X2
|
$4.43 Million |
|
Glacier Media Inc
PINK:GLMFF
|
$4.43 Million |
|
Ravelin Properties REIT
TO:RPR-UN
|
$4.43 Million |
|
Dave Inc. Warrants
NASDAQ:DAVEW
|
$4.43 Million |
|
NeoTerrex Minerals Inc.
V:NTX
|
$4.43 Million |
|
Quantum Genomics SA
PA:ALQGC
|
$4.43 Million |
|
Anew Medical, Inc.
NASDAQ:WENA
|
$4.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ikapharmindo Putramas Tbk.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 244,711,674,310 to 246,124,886,180, a change of 1,413,211,870 (0.6%).
- Net income of 5,014,949,520 contributed positively to equity growth.
- Dividend payments of 3,790,490,630 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp5.01 Billion | +2.04% |
| Dividends Paid | Rp3.79 Billion | -1.54% |
| Other Changes | Rp188.75 Million | +0.08% |
| Total Change | Rp- | 0.58% |
Book Value vs Market Value Analysis
This analysis compares Ikapharmindo Putramas Tbk.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.46x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.04x to 1.46x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | Rp104.89 | Rp214.00 | x |
| 2023-12-31 | Rp145.26 | Rp214.00 | x |
| 2024-12-31 | Rp146.10 | Rp214.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ikapharmindo Putramas Tbk. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.22%
- • Asset Turnover: 0.84x
- • Equity Multiplier: 2.00x
- Recent ROE (2.04%) is below the historical average (5.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 9.38% | 4.16% | 1.03x | 2.19x | Rp-1.09 Billion |
| 2023 | 6.27% | 3.48% | 0.95x | 1.89x | Rp-9.13 Billion |
| 2024 | 2.04% | 1.22% | 0.84x | 2.00x | Rp-19.60 Billion |
Industry Comparison
This section compares Ikapharmindo Putramas Tbk.'s net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $116,780,933,110
- Average return on equity (ROE) among peers: 20.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ikapharmindo Putramas Tbk. (IKPM) | Rp236.96 Billion | 9.38% | 1.01x | $4.43 Million |
| Multi Medika Internasional (MMIX) | $1.35 Billion | 26.08% | 1.40x | $15.50 Million |
| Penta Valent (PEVE) | $232.21 Billion | 15.58% | 2.90x | $9.94 Million |